Clinical Trial Update: A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial is evaluating the safety and expression of delandistrogene moxeparvovec (SRP-9001) in participants with Duchenne muscular dystrophy.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• SRP-9001 (delandistrogene moxeparvovec)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Muscular Dystrophy, Duchenne | Phase 1 | Status: RECRUITING